deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03053102

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria

Sponsor: Achillion, a wholly owned subsidiary of Alexion

Conditions Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions Danicopan
Updated 16 times since 2017 Last updated: May 31, 2022 Started: Mar 31, 2017 Primary completion: Nov 14, 2018 Completion: Nov 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03053102, this PHASE2 trial focuses on Paroxysmal Nocturnal Hemoglobinuria (PNH) and remains completed. Sponsored by Achillion, a wholly owned subsidiary of Alexion, it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~May 2018 · 11 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Sep 2019 · 8 months · monthly snapshot~Sep 2019 – ~Jun 2020 · 9 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Apr 2023 · 9 months · monthly snapshot~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2023 — Dec 2023 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Jul 2022 — Apr 2023 [monthly]

    Completed PHASE2

  2. Sep 2021 — Jul 2022 [monthly]

    Completed PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

  4. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE2

  5. Sep 2019 — Jun 2020 [monthly]

    Completed PHASE2

  6. Jan 2019 — Sep 2019 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  7. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  8. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Jun 2017 — May 2018 [monthly]

    Recruiting PHASE2

  10. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Achillion, a wholly owned subsidiary of Alexion
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations